Clinical Trial Update: Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

This Phase 1 study assessed the safety and preliminary activity of combining bortezomib with gemcitabine and carboplatin in patients with advanced or recurrent …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Effusion
• Non-small Cell Lung Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Paraplatin (Carboplatin)
• Velcade (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED